---
document_datetime: 2024-11-28 10:41:32
document_pages: 30
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/puregon-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: puregon-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 18.9636971
conversion_datetime: 2025-12-28 04:37:58.62132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Puregon

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0130              | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 19/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/1465/ 202305   | Periodic Safety Update EU Single assessment - follitropin beta                                                                                                                                                                               | 25/01/2024   | 27/03/2024   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1465/202305.   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0129              | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                 | 13/02/2024   | n/a          |               |                                                                                                                                             |
| IB/0126              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 28/03/2023   | 27/03/2024   | SmPC and PL   |                                                                                                                                             |
| IA/0125              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 10/10/2022   | n/a          |               |                                                                                                                                             |
| II/0124              | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                 | 01/09/2022   | n/a          |               |                                                                                                                                             |
| N/0123               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 27/10/2021   | 27/03/2024   | PL            |                                                                                                                                             |
| II/0122              | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                 | 30/09/2021   | n/a          |               |                                                                                                                                             |
| IB/0121              | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                           | 15/09/2021   | n/a          |               |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------|
| T/0120    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/05/2021 | 04/06/2021 | SmPC, Labelling and PL |                              |
| IB/0119/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 23/04/2021 | 04/06/2021 | Annex II               | batch control/testing takes  |
| IA/0118   | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/03/2021 | n/a        |                        |                              |
| IB/0116/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of                                                                                                                                                                                                                                                                                                                            | 15/02/2021 | n/a        |                        | the finished or intermediate |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the manufacturing process B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|
| II/0112/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 28/01/2021 | n/a | B.II.d.2.a |

<div style=\"page-break-after: always\"></div>

|           | product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0111/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a                                                                                                                                                                                                                                                                                                                                                                                     | 28/01/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                            |            |            |    |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0117             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                           | 18/01/2021 | 04/06/2021 | PL |                                   |
| II/0113            | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                               | 14/01/2021 | n/a        |    |                                   |
| PSUSA/1465/ 202005 | Periodic Safety Update EU Single assessment - follitropin beta                                                                                                                                                                                                                                                                                                                                             | 14/01/2021 | n/a        |    | PRAC Recommendation - maintenance |
| N/0115             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                           | 11/12/2020 | 04/06/2021 | PL |                                   |
| IA/0114/G          | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging | 23/11/2020 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|         | devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                              |            |            |                                  | components or   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------|
| IB/0110 | C.I.7.a - Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                       | 29/09/2020 | 05/11/2020 | SmPC, Labelling and PL           |                 |
| IB/0107 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                 | 13/08/2020 | n/a        |                                  |                 |
| IB/0108 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                      | 01/07/2020 | 05/11/2020 | SmPC, Annex II, Labelling and PL |                 |
|         | This was an application for a group of variations. B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a | 05/06/2020 | n/a        |                                  | II/0106/G       |

<div style=\"page-break-after: always\"></div>

|         | method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0105 | B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/02/2020 | n/a        |                        |                                                                                                                                                                                                                                                                    |
| WS/1702 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to revise the safety information regarding Ovarian Hyperstimulation Syndrome (OHSS) to replace clinical advice describing specific interventions with the recommendation to follow current clinical practice for reducing the risk of OHSS during Assisted Reproductive Technology (ART), based on post-marketing data and literature review. The package Leaflet is updated accordingly. In addition, the worksharing applicant took the opportunity to update the list of local representatives in the Package Leaflet and made some editorial changes in the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/11/2019 | 05/11/2020 | SmPC, Labelling and PL | Follow current clinical practice for reducing the risk of OHSS during Assisted Reproductive Technology (ART). Adherence to the recommended Fertavid dose and treatment regimen and careful monitoring of ovarian response is important to reduce the risk of OHSS. |

<div style=\"page-break-after: always\"></div>

|           | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2019   | n/a        |              | IB/0103                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------|----------------------------|
| WS/1502   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal to a protocol                                                                                                                            | 16/05/2019   | n/a        |              | product and is not related |
| IG/1062   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/02/2019   | n/a        |              |                            |
| WS/1457/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 13/12/2018   | n/a        |              |                            |
| IG/0968   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/09/2018   | 04/10/2019 | Annex II and |                            |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            | PL                     |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| WS/1339/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation | 12/07/2018 | n/a        |                        |                                   |
| T/0097             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/06/2018 | 06/07/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/1465/ 201705 | Periodic Safety Update EU Single assessment - follitropin beta                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/11/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| WS/1186/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test                                                                                                                                                                                   | 13/07/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                       |            |            |           | method or a method   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|----------------------|
| WS/1124   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS | 21/04/2017 | n/a        |           |                      |
| N/0093    | Minor change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                        | 02/03/2017 | 28/04/2017 | Labelling | connected            |
| IG/0762   | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                                                                                                                                                     | 26/01/2017 | n/a        |           |                      |
| IG/0730   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                | 10/10/2016 | n/a        |           |                      |
| WS/0975/G | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                              | 15/09/2016 | n/a        |           |                      |

<div style=\"page-break-after: always\"></div>

|           | 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol   |            |            |                                  | Article   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------|
| IG/0703/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                               | 18/07/2016 | n/a        |                                  |           |
| IB/0087   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/05/2016 | 28/04/2017 | SmPC, Annex II, Labelling and PL |           |
| IG/0545/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/04/2015 | n/a        |                                  |           |

<div style=\"page-break-after: always\"></div>

|           | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |     |                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/0691   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                   | 26/03/2015 | n/a |                                   |
| PSUV/0082 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/12/2014 | n/a | PRAC Recommendation - maintenance |
| WS/0627   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of a site where batch control/testing takes place for the finished product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                | 20/11/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |    |                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------------------------|
| N/0084    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/11/2014 | 19/12/2014 | PL |                                          |
| WS/0571/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes in the test procedure of the AS. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 25/09/2014 | n/a        |    | Changes in the test procedure of the AS. |
| IG/0449/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/07/2014 | n/a        |    |                                          |

<div style=\"page-break-after: always\"></div>

|           | intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0487/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes to the manufacturing process of the finished product. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                               | 20/03/2014 | n/a |

<div style=\"page-break-after: always\"></div>

| WS/0465   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Product Information (PI) to address common medical knowledge concerning assisted reproduction technology regarding : monitoring of ovarian response (SmPC section 4.2) ; updates regarding infertility evaluation before starting treatment, multiple pregnancy, ectopic pregnancy, ovarian hyperstimulation syndrome, ovarian torsion, ovarian and other reproductive system neoplasms, vascular complications, other medical conditions (SmPC section 4.4). The Package leaflet is updated accordingly. The MAH is taking the opportunity to update the PI in line with QRD template version 9 and to make other editorial corrections. In addition, the details of the local representative of Croatia have been included in the German, Greek, Spanish and Italian PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 20/02/2014   | 19/12/2014   | SmPC, Annex II, Labelling and PL   | The Company has updated the product information, and has referred to published literature and the QRD template to justify changes in the wording of sections 4.2, 4.4 and 4.6 of the SmPC. The Company has revised wording of section 4.2 and 4.4 of the SPC to reflect current clinical practice in the management of fertility that recommends use of ultrasound images to guide management with the medicinal product by following follicular development and by detecting multi-fetal gestations. The Company has introduced information to section 4.4 of the SmPC on management of the ovarian hyper-stimulation syndrome. The revised wording is acceptable and is considered to enhance clinical safety of patients. Grammatical changes have been made to sections 4.4, 4.6, 4.8 and 5 of the SmPC to improve clarity of meaning on use of the medicinal product and to comply with the QRD template; furthermore minor editorial corrections were made throughout the SmPC. These changes are also acceptable. The PL has been updated in order to reflect the SmPC changes described above. Overall, the changes to the product information texts are considered to improve clinical safety and so the benefit / risk balance of the current product in the stated indications   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0078/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/12/2013   | 19/12/2014   | Annex II and PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IG/0366   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                                                                                                                                           | 08/11/2013   | n/a        |                                  | PSMF location                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------|
| T/0075    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/08/2013   | 12/09/2013 | SmPC, Labelling and PL           |                               |
| IG/0225   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                              | 26/02/2013   | n/a        |                                  |                               |
| WS/0228/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the active substance B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 19/04/2012   | n/a        |                                  | material/intermediate/reagent |
| IA/0071/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/01/2012   | 26/03/2012 | SmPC, Annex II, Labelling and PL |                               |

<div style=\"page-break-after: always\"></div>

|           | product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                            |            |     |                                  | and/or address of a manufacturer   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|------------------------------------|
| N/0072    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/12/2011 | n/a | PL                               |                                    |
| IB/0067/G | This was an application for a group of variations. 1. Type IB variation regarding a deletion of a complete pharmaceutical form; i.e. all strengths and presentations of the pharmaceutical form Powder and solvent for solution for injection [EU/1/96/008/001-016]. The deletion will require an update of Annex I, IIA, IIIA and IIIB of the Complete set of Annexes. 2. Type IB variation regarding a deletion of one of the strengths of the pharmaceutical form Solution for injection; i.e. 250 IU/0.5 ml Solution for Injection, all presentations [EU/1/96/008/035-037]. The deletion will require an update of Annex I, IIA, IIIA and IIIB of the Complete set of Annexes. Background of the changes: | 12/08/2011 | n/a | SmPC, Annex II, Labelling and PL |                                    |

<div style=\"page-break-after: always\"></div>

| [1] Type IB - C.I.7.a Deletion EU/1/96/008/001-016 - The Puregon Powder and injection (Puregon Powder) the first pharmaceutical in the initial application in Puregon Powder pharmaceutical in four strengths each with (including both ampoule-ampoule combinations). Since then, Solution for injection in vials injection in cartridges (for have been approved and Powder presentations are therefore the powder presentations off the market in the EU Puregon Solution for injection in vials. marketed in any country 2010. [2] Type IB - C.I.7.b Deletion EU/1/96/008/035-036 - In this submission the MAH one of the strengths of Puregon in vials (250 IU/0.5 ml). strenght of the approved injections in vials, next to 100, 150, 200 and 225 IU/0.5 IU/0.5 ml in vials has never   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | EU - Deletion of - a pharmaceutical form - Deletion of - a strength                                                                                                                                                                                                                                                                                                               |            |            |    | any C.I.7.a C.I.7.b      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------------|
| N/0066    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                  | 06/07/2011 | n/a        | PL |                          |
| WS/0112   | an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes to the manufacturing process of the drug product B.II.b.3.c - Change in the manufacturing process of the finished product - The product is a biological/immunological medicinal product and the                                      | 17/03/2011 | 17/03/2011 |    | This was change requires |
| WS/0072/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes to the active substance manufacturing process and control. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 17/03/2011 | 17/03/2011 |    |                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0034 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                        | 21/10/2010 | 29/11/2010 | SmPC, Labelling and PL | This type II variation concerns a safety update of the SPC following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Following a re-analysis of safety data a separate warning regarding ovarian torsion is included in the SPC Section 4.4. OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries have been identified as risk factors for ovarian torsion. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. SPC Section 4.8 was amended by including the following adverse reactions in the table concerning treatment in females: abdominal discomfort, constipation, diarrhoea, metrorrhagia, ovarian cyst, ovarian torsion, uterine enlargement, vaginal haemorrhage (uncommon). Headache, rash and injection site pain (common) are included in the table concerning treatment in men. Minor changes in the labelling and other SPC sections (4.1; 4.2; 4.3; 4.6) and corrections of linguistic differences between the Puregon and Fertavid texts were also agreed. The PL is updated accordingly. |
| WS/0033 | This was an application for a variation following a                                                                                                                                                                                                                                                                                         | 23/09/2010 | 25/10/2010 | SmPC                   | Section 5.1 of the SmPC was amended to support the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                  |            |            |                        | current information in Section 4.2. The information added to SmPC 5.1 shows a comparison to urinary FSH, including presentation of study data on (mean) total dosage and treatment period needed. A minor change was also made to the text of SmPC section 4.2.                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0065 | Change to the purification process of the drug substance Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/11/2009 | 08/12/2009 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0063 | Update to the Summary of Product Characteristics (SPC), Labelling and Package Leaflet (PL) to comply with the SPC guideline and version 7.2 of the QRD template. Update to the Package Leaflet following the conduct of a Readability Testing. In addition, the Marketing Authorisation Holder took the opportunity to make some corrections in the SPC and in the Package Leaflet. The MAH also introduced some linguistic corrections in several languages versions of the Annexes. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 22/10/2009 | 23/11/2009 | SmPC, Labelling and PL | The Puregon Product Information was updated to comply with the SPC guideline and version 7.2 of the QRD template by using short terms for the pharmaceutical form in section 3 of the SPC and in section 6 of the Package Leaflet, by using abbreviated terms for the administration route in the Labelling as well as by harmonising the prefixes used in the Labelling. Also the Package Leaflet has been updated following the conduct of a Readability Testing on the Puregon vials Package Leaflet. |
| IA/0064 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/07/2009 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0062   | Changes to a method for the control of the drug substance. Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                   | 19/03/2009   | 24/03/2009   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0061   | Additional manufacturing site for Puregon solution for injection 833 IU/mL. Change(s) to the manufacturing process for the finished product                                                                                                                                                 | 19/02/2009   | 10/03/2009   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0060   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                                          | 14/11/2008   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0058   | Additional site for the testing and final batch release of Puregon solution for injection in a cartridge. Change(s) to the test method(s) and/or specifications for the finished product                                                                                                    | 24/07/2008   | 05/09/2008   | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0059   | This procedure relates to an update of section 4.2 of the SPC requested by the CHMP further to assessment of FUM 010. Section 5.2 of Puregon solution for injection in cartridges (only) has been also updated. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 24/04/2008   | 20/06/2008   | SmPC, Labelling and PL | As requested by the CHMP in their conclusion further to assessment of a Follow-Up Measure (FUM 010), section 4.2 of the SPC (Posology and method of administration) for Puregon was amended, as it made reference to a higher effectiveness of Puregon in comparison to urinary follicle- stimulating hormone (FSH). Reference to this has now been deleted. Section 5.2 of the SPC has been also updated for Puregon solution for injection in cartridges, only. Minor typographical amendments to the SPC and Labelling were also made. Finally, graphical amendments to pictures were |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       | implemented throughout the PL for all presentations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0057 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20/09/2007 | 27/09/2007 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0056 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/04/2007 | n/a        | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0055 | This variation relates to an update of section 4.8 of the Summary of Product Characteristics (SPC) and section 4 of the Package Leaflet (PL) in order to implement the results of the recoding from WHO ART to MedDRA and to the addition of warning on hepatotoxicity in association with ovarian hyperstimulation syndrome in section 4.4 of the SPC. In addition to this, the Marketing Authorisation Holder (MAH) updated the heading of the section 6.6 of the SPC according to the QRD template 7.1. Update of Summary of Product Characteristics and Package Leaflet | 16/11/2006 | 09/01/2007 | SmPC and PL           | The MAH submitted a type II variation to update the section 4.8 of the SPC and section 4 of the PL in order to implement the results of the recoding from WHO ART to MedDRA and to the addition of warning on hepatotoxicity in association with ovarian hyperstimulation syndrome in section 4.4 of the SPC. In addition to this, the MAH updated the heading of the section 6.6 of the SPC according to the QRD template 7.1. The MAH stated, that cases of liver function abnormalities associated with Ovarian Hyperstimulation syndrome (OHSS) have been reported in the literature and clinical guidelines on OHSS include that liver enzymes may be elevated in serious cases of OHSS and should be monitored. The MAH proposed to include a warning in section 4.4 of the SPC that liver function test abnormalities have been observed in cases of severe or moderate OHSS. The following wording has been added: Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with ovarian hyperstimulation syndrome. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                    |            |            |                                  | change from WHO-ART to MedDRA terminology for reporting of adverse drug reactions (ADRs). The Package Leaflet has been amended accordingly.   |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049 | Change to the test procedure and/or specification of a raw material                                | 21/09/2006 | 27/09/2006 |                                  |                                                                                                                                               |
| IB/0053 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 29/08/2006 | n/a        |                                  |                                                                                                                                               |
| IB/0054 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 20/07/2006 | n/a        |                                  |                                                                                                                                               |
| IB/0052 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 20/07/2006 | n/a        |                                  |                                                                                                                                               |
| II/0050 | Change(s) to the test method(s) and/or specifications for the active substance                     | 01/06/2006 | 07/06/2006 |                                  |                                                                                                                                               |
| R/0048  | Renewal of the marketing authorisation.                                                            | 23/03/2006 | 29/05/2006 | SmPC, Annex II, Labelling and PL |                                                                                                                                               |
| II/0047 | Change(s) to the test method(s) and/or specifications for the active substance                     | 14/12/2005 | 21/12/2005 |                                  |                                                                                                                                               |
| N/0046  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 05/08/2005 | n/a        | Labelling                        |                                                                                                                                               |
| IA/0045 | IA_28_Change in any part of primary packaging material not in contact with finished product        | 19/07/2005 | n/a        |                                  |                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IB/0044   | IB_31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                   | 07/12/2004   | n/a        |                                  |                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042   | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                     | 16/09/2004   | 20/10/2004 | SmPC and Labelling               | Decrease of the filling volume of the cartridge of Puregon 300 IU/0.36 ml and 600 IU/0.72 ml: 0.480 ml instead of 0.525 ml for the 300 IU presentation, 0.840 ml instead of 0.885 ml for the 600 IU presentation. |
| II/0041   | Change(s) to container                                                                                                                                                                                                                                                                                             | 23/06/2004   | 02/08/2004 | SmPC                             |                                                                                                                                                                                                                   |
| II/0038   | New presentation(s)                                                                                                                                                                                                                                                                                                | 23/06/2004   | 02/08/2004 | SmPC, Annex II, Labelling and PL | Addition of two new presentations of an already authorised strength (833 IU/ml) of Puregon solution for injection in cartridge: 150 IU/0.18 ml and 900 IU/ 1.08 ml.                                               |
| IB/0039   | IB_43_a_02_Add./replacement/del. of measuring or administration device - deletion                                                                                                                                                                                                                                  | 10/03/2004   | n/a        | SmPC and Labelling               |                                                                                                                                                                                                                   |
| I/0036    | 24_Change in test procedure of active substance                                                                                                                                                                                                                                                                    | 25/09/2003   | 30/09/2003 |                                  |                                                                                                                                                                                                                   |
| I/0037    | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                                                                                                                                                                     | 18/09/2003   | 22/09/2003 |                                  |                                                                                                                                                                                                                   |
| N/0035    | Removal of text from Blister foil for presentations 038 and 039 (the text is the same appearing on the cartridge and the labelling information on the cartridge can be seen through the transparent blister foil) Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 16/07/2003   | 19/08/2003 | Labelling                        |                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0034   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                                                          | 20/03/2003   | 31/03/2003   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033   | 01_Change following modification(s) of the manufacturing authorisation(s) 24_Change in test procedure of active substance Change(s) to the test method(s) and/or specifications for the active substance Change(s) to the test method(s) and/or specifications for the finished product | 25/07/2002   | 28/10/2002   | SmPC and PL | As requested by the CPMP following the assessment of a pharmaceutical Follow-up Measure related to the manufacturing process, section 4.4 of the Summary of Product Characteristics (SPC) and section 2 of the Package Leaflet (PL) were updated. Information regarding the possibility of Puregon to contain traces of streptomycin and/or neomycin that may cause hypersensitivity reactions was included in these sections. In addition, section 4.8 of the SPC and section 4 of the PL were updated to include information regarding the occurrence of rash and erythema based on data from post-marketing experience and assessment of the 6th PSUR. Moreover, other minor changes were introduced in the SPC and PL. |
| I/0031    | 24_Change in test procedure of active substance                                                                                                                                                                                                                                         | 27/06/2002   | 02/07/2002   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| I/0032    | 12_Minor change of manufacturing process of the active substance                                                                                                                                                                                                                        | 30/05/2002   | 06/06/2002   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0030   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                                                          | 30/05/2002   | 04/06/2002   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0029   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                                                          | 21/02/2002   | 19/03/2002   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0026   | Following the first 5-year renewal of the marketing authorisation, the Summary of product Characteristics and package leaflet. Sections 4.4 and 4.6 of the Summary of Product Characteristics (SPC)                                                                                     | 27/06/2001   | 05/02/2002   | SmPC and PL | Following the first 5-year renewal of the marketing authorisation, the Summary of product Characteristics and package leaflet. Sections 4.4 and 4.6 of the Summary of Product Characteristics (SPC) and section 2 of the Package                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | and section 2 of the Package Leaflet (PL) were updated to include wording on potential multiple births and congenital malformations. Moreover, other minor changes were introduced in the SPC and PL. Update of Summary of Product Characteristics and Package Leaflet   |            |            |                                  | Leaflet (PL) were updated to include wording on potential multiple births and congenital malformations. Moreover, other minor changes were introduced in the SPC and PL.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                         | 31/10/2001 | 08/03/2002 | Labelling                        |                                                                                                                                                                            |
| I/0027  | 20_Extension of shelf-life as foreseen at time of authorisation                                                                                                                                                                                                          | 13/07/2001 | 18/10/2001 | SmPC                             |                                                                                                                                                                            |
| R/0024  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                  | 28/03/2000 | 26/07/2001 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                            |
| II/0023 | Extension of Indication                                                                                                                                                                                                                                                  | 14/12/2000 | 10/04/2001 | SmPC and PL                      |                                                                                                                                                                            |
| II/0020 | 01_Change following modification(s) of the manufacturing authorisation(s) Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                 | 28/08/2000 | 19/01/2001 |                                  |                                                                                                                                                                            |
| I/0022  | 01_Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                | 10/10/2000 | 15/01/2001 |                                  |                                                                                                                                                                            |
| II/0018 | Change(s) to shelf-life or storage conditions                                                                                                                                                                                                                            | 29/06/2000 | 08/12/2000 | SmPC, Labelling and PL           |                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics, Labelling and Package Leaflet                      | 29/06/2000   | 08/12/2000   | SmPC, Labelling and PL           | II/0016   |
|---------|--------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------|
| I/0021  | 15a_Change in IPCs applied during the manufacture of the product                                 | 22/09/2000   | n/a          |                                  |           |
| I/0019  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 25/07/2000   | 28/08/2000   |                                  |           |
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 07/04/2000   | 11/07/2000   | Labelling and PL                 |           |
| II/0011 | Update of Summary of Product Characteristics, Labelling and Package Leaflet                      | 23/09/1999   | 21/02/2000   | SmPC, Annex II, Labelling and PL |           |
| X/0010  | X-3-iii_Addition of new strength                                                                 | 23/09/1999   | 10/02/2000   | SmPC, Annex II, Labelling and PL |           |
| II/0013 | Change(s) to the test method(s) and/or specifications for the active substance                   | 23/09/1999   | 22/12/1999   |                                  |           |
| I/0015  | 24_Change in test procedure of active substance                                                  | 14/12/1999   | 22/12/1999   |                                  |           |
| N/0014  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 21/10/1999   | 21/02/2000   | Labelling and PL                 |           |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 28/05/1999   | 08/07/1999   | Labelling                        |           |
| X/0009  | X-3-iv_Change or addition of a new pharmaceutical                                                | 19/11/1998   | 26/04/1999   | SmPC, Annex                      |           |

<div style=\"page-break-after: always\"></div>

|         | form                                                                      |            |            | II, Labelling and PL   |
|---------|---------------------------------------------------------------------------|------------|------------|------------------------|
| II/0008 | Update of Summary of Product Characteristics and Package Leaflet          | 22/04/1998 | 05/10/1998 | SmPC and PL            |
| I/0007  | 01_Change following modification(s) of the manufacturing authorisation(s) | 17/01/1997 | 03/04/1997 | Annex II and PL        |
| I/0006  | 01_Change following modification(s) of the manufacturing authorisation(s) | 17/01/1997 | 03/04/1997 | Annex II and PL        |
| I/0005  | 01_Change following modification(s) of the manufacturing authorisation(s) | 17/01/1997 | 03/04/1997 | Annex II and PL        |
| T/0004  | Transfer of Marketing Authorisation                                       | 04/09/1996 | 20/01/1997 | SmPC, Labelling and PL |
| I/0003  | 24_Change in test procedure of active substance                           | 12/09/1996 | 28/11/1996 |                        |
| I/0002  | 13_Batch size of active substance                                         | 12/09/1996 | 28/11/1996 |                        |
| I/0001  | 11_Change in or addition of manufacturer(s) of active substance           | 12/09/1996 | 28/11/1996 | Annex II               |